US-based biotechnology company Inceptor Bio has dosed the first subject in the investigator-initiated trial of its lead ...

Casdatifan, a HIF-2α inhibitor, shows early clinical activity and good tolerance in patients with previously treated clear ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

A research team led by Prof. Jiang Yanyi from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences has ...

Inceptor Bio, a clinical-stage biotechnology company pioneering next-generation cell therapies, today announced that the first patient has been dosed in the clinical trial of IB-T101, the company's ...

All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a ...

Squamous cell lung carcinoma (LUSC) originates from squamous cells and has a high rate of metastasis and recurrence. The lack of effective genetic targets and specific therapies has resulted in a poor ...

Metabolic dysregulation in the development of clear cell renal cell carcinoma (ccRCC) remains to be understood. Here the authors identify that a carnitine synthesis enzyme BBOX1, which inhibits ...

Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based ...

Figure 1: Characterization of the hybrid cell vaccine. The hybrid cell vaccination was well tolerated by all patients. There were no serious adverse effects or any clinical signs of autoimmune ...

Thomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal ...

Background: Lung adenocarcinoma (LUAD) is the most common diagnostic histologic subtype of non-small cell lung cancer, but the role of receptor-type tyrosine-protein phosphatase-like N (PTPRN) in LUAD ...